Pediatric Praziquantel Consortium
Consortium presenting at the ASTMH 65th Annual Meeting
In September, the Pediatric Praziquantel Consortium got acceptance of the abstract ’Outcome of two phase I relative bioavailability studies in healthy volunteers after administration of the new pediatric ODT formulations of racemate Praziquantel (rac-PZQ) and of the active enantiomer of Praziquantel (L-PZQ)’ for ...
Schistosomiasis Control Initiative and Pediatric Praziquantel Consortium join forces in the fight against schistosomiasis
Goal is to make a child-friendly treatment for schistosomiasis accessible to children under six years of age in endemic countries
A story of schistosomiasis infection in Ghana
A story of schistosomiasis infection in Ghana.
Video credit: Shelly Xie
Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.
Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.
Soon after its formation, the consortium established a pediatric drug development program, divided into two major steps: preclinical development, and clinical development.
The pediatric formulation
A new child-appropriate praziquantel formulation is essential for treating children under 6 years of age. This formulation that will use small, orally dispersible tablets with an acceptable taste.